| neuromab起源於2005年和NIMH的合作資助研究。最初成立的目的是建立 neuromabs 神經相關抗體資料庫，初期主要專注於膜蛋白（受體/通道/轉運），突觸蛋白及其他疾病相關的神經訊息傳遞分子。並擴展到包括神經發育、表觀遺傳學和罕見疾病的研究。neuromab產品主要涉及神經科學和生物醫學等基礎研究領域，提供哺乳類動物腦神經研究相關的高品質小鼠單株抗體。 |
NeuroMab 是一個純學術性的小鼠單株抗體（mAb）研發機構，專注於製備經過嚴格驗證的抗體，供神經科學應用，主要用於哺乳動物腦組織的生化與免疫組織化學分析（例如蛋白免疫印跡、免疫組織染色、陣列斷層造影）。
Antibodies — Western Blot、IHC
Parkinson’s disease (PD) : alpha-synuclein (α-syn) and LRRK2
Alzheimer’s disease (AD): Anti-amyloid monoclonal antibodies are the first disease-targeting therapies for early Alzheimer’s disease (AD), approved by the FDA, including aducanumab (Aduhelm®), lecanemab (Leqembi®), and donanemab (Kisunla™). These treatments work by targeting and helping the immune system to clear beta-amyloid plaques, a hallmark protein that accumulates in the brains of people with AD.
The NeuroMab collection (both the mAbs and the hybridoma cells that produce them) is available from the Developmental Studies Hybridoma Bank (DSHB) at the University of Iowa.
Recombinant mAbs derived from the NeuroMab collection are available from Addgene as plasmids and, as funded by BRAIN Initiative award NIH U24 NS119916, as ready-to-use antibodies.
| UC Davis/NIH NeuroMab Facility Disease Targets (derived from OMIM) |
| Ankyrin-B (N105/13, N105/17) LONG QT SYNDROME 4 CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED Ataxin-1 (N76/3, N76/8) SPINOCEREBELLAR ATAXIA 1 CASK (K56A/50) MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA FG SYNDROME 4 MENTAL RETARDATION, X-LINKED, CASK-RELATED CASPR2 (K67/25) CORTICAL DYSPLASIA-FOCAL EPILEPSY SYNDROME AUTISM, SUSCEPTIBILITY TO, TYPE 15 PITT-HOPKINS-LIKE SYNDROME TYPE 1 CNGA1 (L36/12) RETINITIS PIGMENTOSA 49 CNGA3 (L36/12) ROD MONOCHROMACY Cav1.2 (L57/46) TIMOTHY SYNDROME BRUGADA SYNDROME 3 Cav3.2 (N55/10) SUSCEPTIBILITY TO CHILDHOOD ABSENCE EPILEPSY, TYPE 6 SUSCEPTIBILITY TO IDIOPATHIC GENERALIZED EPILEPSY, TYPE 6 Cav beta2 (N8B/1) BRUGADA SYNDROME 4 Cav beta4 (N10/7) SUSCEPTIBILITY TO JUVENILE MYOCLONIC EPILEPSY, TYPE 6 SUSCEPTIBILITY TO GENERALIZED IDIOPATHIC EPILEPSY, TYPE 9 Clcn5 (N237/24) DENT DISEASE TYPE 1 NEPHROLITHIASIS, X-LINKED RECESSIVE HYPOPHOSPHATEMIC RICKETS, X-LINKED RECESSIVE PROTEINURIA, LOW MOLECULAR WEIGHT, WITH HYPERCALCIURIA AND NEPHROCALCINOSIS Contactin (K73/20) MYOPATHY, CONGENITAL, COMPTON-NORTH Copper Atpase 1 (L60/4) MENKES DISEASE, MILD CUTIS LAXA, X-LINKED MENKES DISEASE MENKES DISEASE, COPPER-REPLACEMENT RESPONSIVE OCCIPITAL HORN SYNDROME Copper Atpase 2 (L62/29) WILSON DISEASE Dardarin/LRRK2 (N138/6) PARKINSON DISEASE 8 SUSCEPTIBILITY TO PARKINSON DISEASE Dicer (N167/7) PLEUROPULMONARY BLASTOMA Dopamine D2 receptor (N186/29) MYOCLONUS-DYSTONIA SYNDROME FGF14 (N56/21) SPINOCEREBELLAR ATAXIA 27 Fig4 (N202/7) CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J AMYOTROPHIC LATERAL SCLEROSIS 11 Frataxin (N191/7) FRIEDREICH ATAXIA GABA-A receptor alpha1 (N95/35) SUSCEPTIBILITY TO JUVENILE MYOCLONIC EPILEPSY, TYPE 5 SUSCEPTIBILITY TO CHILDHOOD ABSENCE EPILEPSY, TYPE 4 GABA-A receptor beta3 (N87/25) INSOMNIA SUSCEPTIBILITY TO CHILDHOOD ABSENCE EPILEPSY, TYPE 5 GABA-A receptor delta (N151/3) SUSCEPTIBILITY TO GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 5 GABA-B receptor 2 (N81/2, N81/37) SUSCEPTIBILITY TO NICOTINE DEPENDENCE PROTECTION AGAINST NICOTINE DEPENDENCE GFAP (N206A/8) ALEXANDER DISEASE Gs alpha (N192/12) PSEUDOHYPOPARATHYROIDISM, TYPE IA MCCUNE-ALBRIGHT SYNDROME, SOMATIC, MOSAIC PITUITARY TUMOR, GROWTH HORMONE-SECRETING, SOMATIC PITUITARY ADENOMA, ACTH-SECRETING, SOMATIC PSEUDOPSEUDOHYPOPARATHYROIDISM PSEUDOHYPOPARATHYROIDISM, TYPE IA, WITH TESTOTOXICOSIS OSSEOUS HETEROPLASIA, PROGRESSIVE PSEUDOHYPOPARATHYROIDISM, TYPE IB PROLONGED BLEEDING TIME, BRACHYDACTYLY, AND MENTAL RETARDATION PSEUDOHYPOPARATHYROIDISM, TYPE IC HCN4 (N114/10) SICK SINUS SYNDROME TYPE 2, AUTOSOMAL DOMINANT BRUGADA SYNDROME 8 IP3 receptor type 1 (L24/18) SPINOCEREBELLAR ATAXIA 15 KCNQ1 (N37A/10) LONG QT SYNDROME 1 JERVELL AND LANGE-NIELSEN SYNDROME 1 LONG QT SYNDROME 1, RECESSIVE FAMILIAL ATRIAL FIBRILLATION, TYPE 3 SHORT QT SYNDROME 2 LONG QT SYNDROME 1/2, DIGENIC KCNQ2 (N26A/23) BENIGN NEONATAL EPILEPSY, TYPE 1 BENIGN NEONATAL EPILEPSY, TYPE 1 AND/OR MYOKYMIA KCNQ4 (N43/6) DEAFNESS, AUTOSOMAL DOMINANT TYPE 2A Kir2.1 (N112B/14) ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS SHORT QT SYNDROME 3 Kv1.1 (K20/78, K36/15) EPISODIC ATAXIA, TYPE 1 MYOKYMIA 1 MYOKYMIA 1 WITH HYPOMAGNESEMIA Kv1.5 (K7/45) ATRIAL FIBRILLATION, FAMILIAL, TYPE 7 Laforin (N84/1) PROGRESSIVE MYOCLONIC EPILEPSY, TYPE 2A MMACHC (N230/21) METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE MMP9 (L51/82) METAPHYSEAL ANADYSPLASIA 2, AUTOSOMAL RECESSIVE Malin (N85/18) PROGRESSIVE MYOCLONIC EPILEPSY, TYPE 2B Mfn2 (N153/5) CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2 HEREDITARY MOTOR AND SENSORY NEUROPATHY VI Nav1.1 (K74/71) GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 2 SEVERE MYOCLONIC EPILEPSY OF INFANCY FAMILIAL HEMIPLEGIC MIGRAINE, TYPE 3 INTRACTABLE CHILDHOOD EPILEPSY, WITH GENERALIZED TONIC-CLONIC SEIZURES FAMILIAL FEBRILE CONVULSIONS, TYPE 3A Nav1.2 (K69/3) FEBRILE SEIZURES ASSOCIATED WITH AFEBRILE SEIZURES BENIGN FAMILIAL INFANTILE CONVULSIONS, TYPE 3 Nav1.6 (K87A/10) CEREBELLAR ATROPHY, ATAXIA, AND MENTAL RETARDATION Nav1.7 (N68/6) ERYTHERMALGIA, PRIMARY CHANNELOPATHY-ASSOCIATED INSENSITIVITY TO PAIN PAROXYSMAL EXTREME PAIN DISORDER GENERALIZED EPILEPSY WITH FEBRILE SEIZURES PLUS, TYPE 7 FAMILIAL FEBRILE CONVULSIONS, TYPE 3B Nav beta4 (N168/6) LONG QT SYNDROME 10 Neurexin-1 (N170A/1, N170A/26) PITT-HOPKINS-LIKE SYNDROME TYPE 2 Neuroligin-3 (N110/29) SUSCEPTIBILITY TO AUTISM, X-LINKED, TYPE 1 SUSCEPTIBILITY TO ASPERGER SYNDROME, X-LINKED, TYPE 1 Neuroligin-4 (N98/7, N98/47) SUSCEPTIBILITY TO AUTISM, X-LINKED, TYPE 2 SUSCEPTIBILITY TO ASPERGER SYNDROME, X-LINKED, TYPE 2 MENTAL RETARDATION, X-LINKED OCRL (N166A/26) LOWE OCULOCEREBRORENAL SYNDROME DENT DISEASE TYPE 2 PhyH/PAHX (N210/5) REFSUM DISEASE, ADULT, TYPE 1 Pink1 (N4/15, N4/49) PARKINSON DISEASE TYPE 6, AUTOSOMAL RECESSIVE EARLY-ONSET PARKINSON DISEASE TYPE 6, EARLY-ONSET PARKINSON DISEASE TYPE 6, LATE-ONSET, SUSCEPTIBILITY TO PARKINSON DISEASE, AUTOSOMAL RECESSIVE EARLY-ONSET, DIGENIC, PINK1/DJ1 SAP102 (N19/2) MENTAL RETARDATION, X-LINKED TYPE 90 Shank3 (N69/46) CHROMOSOME 22q13.3 DELETION SYNDROME Slo1 (L6/60) GENERALIZED EPILEPSY AND PAROXYSMAL DYSKINESIA Tafazzin (N173B/13) BARTH SYNDROME CARDIOMYOPATHY, DILATED, TYPE 3A NONCOMPACTION OF LEFT VENTRICULAR MYOCARDIUM, FAMILIAL ISOLATED LEFT VENTRICULAR NONCOMPACTION, ISOLATED TrpM7 (N74/25) SUSCEPTIBILITY TO AMYOTROPHIC LATERAL SCLEROSIS-PARKINSONISM/DEMENTIA COMPLEX TYPE 1 VGlut3 (N34/34) DEAFNESS, AUTOSOMAL DOMINANT TYPE 25 |